Clinical trial · no report yet · Phase 3
RASolute 303
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- NCT07491445 ↗
- Recruiting
- Revolution Medicines, Inc.
- 32 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 14 | |
| YouTube | 9 | |
| Podcasts | 9 |
The trial
ClinicalTrials.gov- Official title
- RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel Versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients With Metastatic Pancreatic Adenocarcinoma
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Pancreatic Cancer; Pancreatic Cancer Metastatic; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; Pancreatic Ductal Adenocarcinoma (PDAC); Pancreatic Adenocarcinoma Metastatic; Pancreatic Adenocarcinoma; Pancreatic Adenosquamous Carcinoma
- Interventions
- daraxonrasib; gemcitabine; nab-paclitaxel
- Arms
- Arm A: daraxonrasib · Experimental
- Arm B: daraxonrasib + gemcitabine and nab-paclitaxel · Experimental
- Arm C: gemcitabine and nab-paclitaxel · Active comparator
- Enrollment
- 900 (estimated)
- Primary outcomes
- Progression free survival (PFS)
- Overall survival (OS)
- Sponsor
- Revolution Medicines, Inc.
- Start
- Mar 9, 2026
- Primary completion
- Jun 2028 (estimated)
- Results posted
- No
- Registry record
- NCT07491445 · updated Oct 2, 2026